BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 25148870)

  • 1. Promoter hypermethylation may be an important mechanism of the transcriptional inactivation of ARRDC3, GATA5, and ELP3 in invasive ductal breast carcinoma.
    Wang D; Yang PN; Chen J; Zhou XY; Liu QJ; Li HJ; Li CL
    Mol Cell Biochem; 2014 Nov; 396(1-2):67-77. PubMed ID: 25148870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequent promoter hypermethylation of BRCA2, CDH13, MSH6, PAX5, PAX6 and WT1 in ductal carcinoma in situ and invasive breast cancer.
    Moelans CB; Verschuur-Maes AH; van Diest PJ
    J Pathol; 2011 Oct; 225(2):222-31. PubMed ID: 21710692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aberrant methylation of ATG2B, ATG4D, ATG9A and ATG9B CpG island promoter is associated with decreased mRNA expression in sporadic breast carcinoma.
    Zhang X; Li C; Wang D; Chen Q; Li CL; Li HJ
    Gene; 2016 Sep; 590(2):285-92. PubMed ID: 27265029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequent aberrant DNA methylation of ABCB1, FOXC1, PPP2R2B and PTEN in ductal carcinoma in situ and early invasive breast cancer.
    Muggerud AA; Rønneberg JA; Wärnberg F; Botling J; Busato F; Jovanovic J; Solvang H; Bukholm I; Børresen-Dale AL; Kristensen VN; Sørlie T; Tost J
    Breast Cancer Res; 2010; 12(1):R3. PubMed ID: 20056007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening of significantly hypermethylated genes in breast cancer using microarray-based methylated-CpG island recovery assay and identification of their expression levels.
    Lian ZQ; Wang Q; Li WP; Zhang AQ; Wu L
    Int J Oncol; 2012 Aug; 41(2):629-38. PubMed ID: 22581028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Promoter CpG island hypermethylation during breast cancer progression.
    Park SY; Kwon HJ; Lee HE; Ryu HS; Kim SW; Kim JH; Kim IA; Jung N; Cho NY; Kang GH
    Virchows Arch; 2011 Jan; 458(1):73-84. PubMed ID: 21120523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CpG island methylation profile of estrogen receptor alpha in Iranian females with triple negative or non-triple negative breast cancer: new marker of poor prognosis.
    Ramezani F; Salami S; Omrani MD; Maleki D
    Asian Pac J Cancer Prev; 2012; 13(2):451-7. PubMed ID: 22524805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein expression and methylation of MGMT, a DNA repair gene and their correlation with clinicopathological parameters in invasive ductal carcinoma of the breast.
    Asiaf A; Ahmad ST; Malik AA; Aziz SA; Rasool Z; Masood A; Zargar MA
    Tumour Biol; 2015 Aug; 36(8):6485-96. PubMed ID: 25820821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Promoter hypermethylation in ductal carcinoma in situ of the male breast.
    Vermeulen MA; van Deurzen CHM; Doebar SC; de Leng WWJ; Martens JWM; van Diest PJ; Moelans CB
    Endocr Relat Cancer; 2019 Jun; 26(6):575-584. PubMed ID: 30921768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The promoter methylation status and mRNA expression levels of CTCF and SIRT6 in sporadic breast cancer.
    Wang D; Li C; Zhang X
    DNA Cell Biol; 2014 Sep; 33(9):581-90. PubMed ID: 24842653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Promoter hypermethylation of ARID1A gene is responsible for its low mRNA expression in many invasive breast cancers.
    Zhang X; Sun Q; Shan M; Niu M; Liu T; Xia B; Liang X; Wei W; Sun S; Zhang Y; Liu XS; Song Q; Yang Y; Ma Y; Liu Y; Yang L; Ren Y; Zhang G; Pang D
    PLoS One; 2013; 8(1):e53931. PubMed ID: 23349767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of promoter hypermethylation of DNA repair genes in tumor and serum DNA in invasive ductal breast carcinoma patients.
    Sharma G; Mirza S; Parshad R; Srivastava A; Gupta SD; Pandya P; Ralhan R
    Life Sci; 2010 Jul; 87(3-4):83-91. PubMed ID: 20470789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methylation of the TPEF- and PAX6-promoters is increased in early bladder cancer and in normal mucosa adjacent to pTa tumours.
    Hellwinkel OJ; Kedia M; Isbarn H; Budäus L; Friedrich MG
    BJU Int; 2008 Mar; 101(6):753-7. PubMed ID: 18070176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Detection and clinical significance of Notch1 methylation in breast cancer and intraductal proliferative breast lesions].
    Zhang N; Sun ZZ; Li F; Cao YW; Zhao CX; Liang WH; Sun HP; Li HA; Fu XG
    Zhonghua Bing Li Xue Za Zhi; 2011 May; 40(5):324-9. PubMed ID: 21756827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Susceptibility of nonpromoter CpG islands to de novo methylation in normal and neoplastic cells.
    Nguyen C; Liang G; Nguyen TT; Tsao-Wei D; Groshen S; Lübbert M; Zhou JH; Benedict WF; Jones PA
    J Natl Cancer Inst; 2001 Oct; 93(19):1465-72. PubMed ID: 11584062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of inactivation of E-cadherin in breast carcinoma: modification of the two-hit hypothesis of tumor suppressor gene.
    Cheng CW; Wu PE; Yu JC; Huang CS; Yue CT; Wu CW; Shen CY
    Oncogene; 2001 Jun; 20(29):3814-23. PubMed ID: 11439345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of Maspin promoter methylation and loss of its protein expression in invasive ductal breast carcinoma: correlation with VEGF-A and MTA1 expression.
    Sharma G; Mirza S; Parshad R; Srivastava A; Gupta SD; Pandya P; Ralhan R
    Tumour Biol; 2011 Feb; 32(1):23-32. PubMed ID: 20697987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aberrant methylation of tumour suppressor genes WT1, GATA5 and PAX5 in hepatocellular carcinoma.
    Mžik M; Chmelařová M; John S; Laco J; Slabý O; Kiss I; Bohovicová L; Palička V; Nekvindová J
    Clin Chem Lab Med; 2016 Dec; 54(12):1971-1980. PubMed ID: 27171388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Protein Expression and Methylation of DAPK1 with Clinicopathological Features in Invasive Ductal Carcinoma Patients from Kashmir.
    Asiaf A; Ahmad ST; Malik AA; Aziz SA; Zargar MA
    Asian Pac J Cancer Prev; 2019 Mar; 20(3):839-848. PubMed ID: 30912402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methylation in the p53 promoter is a supplementary route to breast carcinogenesis: correlation between CpG methylation in the p53 promoter and the mutation of the p53 gene in the progression from ductal carcinoma in situ to invasive ductal carcinoma.
    Kang JH; Kim SJ; Noh DY; Park IA; Choe KJ; Yoo OJ; Kang HS
    Lab Invest; 2001 Apr; 81(4):573-9. PubMed ID: 11304577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.